MERTK (MER Proto-Oncogene, Tyrosine Kinase) is a critical receptor tyrosine kinase belonging to the TAM family (TYRO3, AXL, MERTK) that plays essential roles in phagocytosis, cell survival, and immune regulation within the central nervous system (CNS)[1]. Originally identified as a proto-oncogene, MERTK has emerged as a pivotal regulator of microglial function in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[2]. The gene encodes a transmembrane receptor tyrosine kinase that is primarily expressed in macrophages, microglia, photoreceptor cells, and neurons, where it mediates the clearance of apoptotic cells and cellular debris through recognition of phosphatidylserine exposed on dying cell membranes[3].
The significance of MERTK in neurodegeneration has become increasingly apparent as research reveals its central role in microglial phagocytosis—the process by which immune cells engulf and remove dead cells, protein aggregates, and cellular debris. In Alzheimer's disease, MERTK-mediated phagocytosis is crucial for clearing amyloid-beta plaques, while in Parkinson's disease, it may contribute to alpha-synuclein clearance[4]. Dysregulation of MERTK signaling has been implicated in impaired phagocytosis observed in neurodegenerative conditions, suggesting therapeutic targeting of this receptor could provide beneficial effects[5].
This comprehensive examination explores MERTK's structure, signaling mechanisms, expression patterns, disease associations, and therapeutic potential in neurodegenerative disorders. Understanding the multifaceted roles of MERTK provides insights into disease mechanisms and identifies potential therapeutic targets for intervention in progressive neurological conditions.
The MERTK gene (NCBI Gene ID: 10488, Ensembl ID: ENSG00000153208) is located on chromosome 2q14.1, spanning approximately 45 kilobases of genomic DNA. The gene consists of 20 exons encoding a full-length receptor tyrosine kinase of 1,998 amino acids[1:1]. The chromosomal region 2q14.1 has been implicated in various neurological conditions, and copy number variations encompassing MERTK have been reported in neurodevelopmental disorders.
The MERTK promoter region contains several transcription factor binding sites including NF-κB, AP-1, and STAT response elements, enabling regulation by inflammatory cytokines and growth factors. Polymorphisms in the MERTK promoter have been associated with altered gene expression and modified risk of Alzheimer's disease[6]. Epigenetic regulation through DNA methylation also contributes to MERTK expression patterns in different cell types and disease states.
The MERTK protein (UniProt ID: Q12866, OMIM: 604705) possesses a complex domain architecture enabling its diverse functions:
Extracellular Domain (1-500 amino acids): The N-terminal extracellular region contains two immunoglobulin-like (Ig-like) domains (D1 and D2) and two fibronectin type III (FNIII) domains. The Ig-like domains mediate protein-protein interactions and are essential for ligand binding, particularly recognition of phosphatidylserine through bridging proteins Gas6 and Protein S[1:2]. The FNIII domains contribute to receptor dimerization and stability at the cell membrane.
Transmembrane Domain (501-525 amino acids): A single-pass transmembrane helix anchors the receptor in the lipid bilayer, facilitating proper localization and enabling signal transduction across the membrane.
Cytoplasmic Kinase Domain (526-998 amino acids): The intracellular portion contains the catalytic tyrosine kinase domain responsible for autophosphorylation and downstream signaling. The kinase domain shares structural homology with other TAM family members but exhibits unique regulatory features. Key tyrosine residues (Y749, Y753, Y754, Y867, Y872) serve as phosphorylation sites mediating interaction with adaptor proteins including GRB2, PLCγ, and phosphatidylinositol 3-kinase (PI3K)[7].
Multiple MERTK isoforms have been identified through alternative splicing:
The ratio between membrane-bound and soluble MERTK forms influences phagocytic activity and may be dysregulated in neurodegenerative diseases[2:1].
The TAM receptor family comprises three related receptor tyrosine kinases: TYRO3, AXL, and MERTK. These receptors share common structural features and ligand recognition patterns, having evolved from a common ancestor with distinct but overlapping functions[1:3]. In mammals, all three TAM receptors are expressed, with species-specific expression patterns and functional specializations.
TYRO3 was the first TAM receptor identified, originally as a proto-oncogene in chickens. It is expressed primarily in the nervous system, particularly in neurons and oligodendrocytes, where it regulates synaptic function and myelination.
AXL (from "anexelekto," Greek for "uncontrolled") was discovered as a transforming gene in chronic myeloid leukemia. It is widely expressed in immune cells, endothelial cells, and various tissues, playing roles in cell survival, migration, and innate immunity.
MERTK (from "rat sarcoma virus oncogene homolog") is the most closely related to TYRO3 in terms of ligand specificity and is predominantly expressed in cells of the myeloid lineage, especially macrophages and microglia[1:4].
Both Gas6 (Growth Arrest Specific 6) and Protein S serve as shared ligands for all three TAM receptors, though with differential binding affinities:
The ligand-mediated activation of TAM receptors enables them to function as "phosphatidylserine receptors" that recognize and respond to apoptotic cells expressing this phospholipid on their outer membrane leaflet. This mechanism is essential for efficient phagocytosis of dying cells without triggering inflammatory responses.
MERTK activation occurs through multiple mechanisms:
Ligand-Dependent Activation: Binding of Gas6 or Protein S to the extracellular domain induces receptor dimerization and autophosphorylation on key tyrosine residues. The Gla domain of these ligands bridges apoptotic cells bearing phosphatidylserine to MERTK on phagocytes, creating a molecular bridge enabling recognition and engulfment[3:2].
Ligand-Independent Activation: MERTK can also be activated through:
Constitutive Activity: Some MERTK mutations associated with retinitis pigmentosa result in constitutive kinase activity, suggesting tight regulation is essential for normal function[8].
Activated MERTK triggers multiple downstream signaling pathways:
PI3K/AKT Pathway: MERTK activates PI3K (phosphatidylinositol 3-kinase) leading to AKT phosphorylation. The PI3K/AKT pathway promotes:
This pathway is particularly important for neuronal survival in neurodegenerative contexts[9].
MAPK/ERK Pathway: Through RAS/RAF/MEK/ERK signaling, MERTK regulates:
JAK/STAT Pathway: MERTK can activate STAT proteins, particularly STAT3, leading to:
NF-κB Pathway: MERTK signaling can modulate NF-κB activity, with complex context-dependent effects:
PLCγ and Calcium Signaling: Phospholipase C gamma (PLCγ) activation leads to:
MERTK mediates phagocytosis through several coordinated mechanisms:
Phosphatidylserine Recognition: The Gas6/Gla domain bridges phosphatidylserine on apoptotic cells to MERTK, providing specific recognition of dying cells versus healthy cells[3:3].
Actin Cytoskeleton Remodeling: MERTK signaling activates small GTPases (RAC1, CDC42) that reorganize the actin cytoskeleton, forming phagocytic cups around target particles.
Phagosome Maturation: Following engulfment, MERTK signaling contributes to phagosome maturation through fusion with lysosomes, enabling degradation of phagocytosed material.
Anti-inflammatory Signaling: MERTK activation promotes an anti-inflammatory (M2-like) microglial phenotype, suppressing production of pro-inflammatory cytokines while enhancing anti-inflammatory mediators[10:1].
Within the CNS, MERTK is predominantly expressed in microglia, the resident immune cells of the brain[11]:
Microglial Expression: MERTK is highly expressed in microglia throughout the brain, with highest levels in regions with high neuronal density. Microglial MERTK expression is dynamic, increasing in response to injury or disease. In the aging brain and in neurodegenerative conditions, MERTK expression is often dysregulated, contributing to impaired phagocytic function[4:1].
Neuronal Expression: Lower levels of MERTK are expressed in certain neuronal populations, particularly in the retina and specific brain regions. Neuronal MERTK may function in autocrine or paracrine signaling with microglial MERTK.
Astrocyte Expression: Astrocytes express variable levels of MERTK, with increased expression in reactive astrocytes surrounding pathological lesions. Astrocyte MERTK may contribute to debris clearance in collaboration with microglia[12].
MERTK is expressed in various peripheral tissues and cell types:
MERTK plays complex and multifaceted roles in Alzheimer's disease pathogenesis:
Amyloid-Beta Clearance: MERTK-mediated microglial phagocytosis contributes to clearance of amyloid-beta plaques[9:1]. However, in Alzheimer's disease, microglial MERTK function is often impaired, leading to accumulation of amyloid deposits. The mechanisms underlying this impairment include:
Neuroinflammation: MERTK signaling modulates neuroinflammation in AD:
Synaptic Pruning: During development, microglia prune excess synapses through MERTK-dependent mechanisms[11:1]. In AD, dysregulated synaptic pruning may contribute to synaptic loss. The role of MERTK in adult synaptic pruning remains an area of active investigation.
Genetic Associations: Polymorphisms in the MERTK gene have been associated with Alzheimer's disease risk[6:1]. Some variants may affect:
Therapeutic Implications: Given its central role in phagocytosis, MERTK represents a promising therapeutic target[13]:
In Parkinson's disease, MERTK is implicated in multiple pathogenic processes:
Alpha-Synuclein Clearance: Microglial MERTK may contribute to clearance of alpha-synuclein aggregates, the pathological hallmark of PD. Impaired MERTK function could contribute to accumulation of toxic aggregates.
Dopaminergic Neuron Survival: MERTK signaling provides trophic support to dopaminergic neurons[14]. Loss of MERTK function may make neurons more vulnerable to toxic insults.
Neuroinflammation: Similar to AD, MERTK modulates microglial activation in PD. Dysregulated MERTK may contribute to chronic neuroinflammation observed in PD brains.
Mitochondrial Function: Emerging evidence suggests MERTK may influence mitochondrial function in neurons and glia, potentially relevant to PD pathogenesis where mitochondrial dysfunction plays a central role.
MERTK is implicated in ALS through several mechanisms:
Microglial Activation: In ALS, microglia adopt a primarily pro-inflammatory phenotype. MERTK downregulation in microglia may contribute to this shift, reducing anti-inflammatory signaling.
Neuronal Debris Clearance: MERTK-mediated phagocytosis is important for clearing debris from dying motor neurons. Impaired clearance may prolong inflammatory responses.
Astrocyte Involvement: Reactive astrocytes in ALS may have altered MERTK expression, affecting their supportive functions.
MERTK mutations cause autosomal recessive retinitis pigmentosa, characterized by:
Photoreceptor Degeneration: MERTK is essential for phagocytosis of photoreceptor outer segments by retinal pigment epithelium (RPE) cells. Mutations impair this process, leading to accumulation of outer segments and subsequent photoreceptor death[8:2].
Clinical Features:
Gene Therapy: AAV-mediated MERTK gene therapy has shown promise in preclinical models and early clinical trials[15], representing a potential treatment for MERTK-associated retinal degeneration.
In multiple sclerosis and related demyelinating disorders:
Myelin Debris Clearance: MERTK-mediated phagocytosis contributes to clearance of myelin debris after demyelination, facilitating remyelination.
Microglial Activation: MERTK regulates microglial activation states in the demyelinating CNS.
Therapeutic Potential: TAM receptor agonists are being investigated for promoting repair in demyelinating diseases.
Activating MERTK signaling could provide therapeutic benefits in neurodegeneration:
Mechanism: Agonists would enhance:
Development Status: Several approaches are being explored:
In certain contexts, MERTK inhibition may be beneficial:
Excessive Phagocytosis: Overactive MERTK may contribute to excessive pruning of synapses or吞噬 normal cells
Cancer Applications: MERTK inhibitors are primarily developed for oncology, where they target tumor-associated macrophages
AAV-mediated gene therapy approaches are being developed:
For Retinitis Pigmentosa: MERTK gene replacement has shown efficacy in animal models and early human trials[15:1]
For Neurodegeneration: CNS-delivered MERTK gene therapy faces challenges:
MERTK and its ligands may serve as biomarkers:
Soluble MERTK: Levels in cerebrospinal fluid (CSF) may reflect microglial activation status
Gas6: CSF Gas6 levels correlate with disease severity in some neurodegenerative conditions
Several key questions remain regarding MERTK in neurodegeneration:
Mechanistic Specificity: How does MERTK specifically recognize different substrates (apoptotic cells, protein aggregates, cellular debris)?
Cell Type-Specific Effects: What are the differential roles of neuronal versus microglial MERTK?
Therapeutic Window: What is the optimal level of MERTK activation for therapeutic benefit?
Biomarkers: Can MERTK-related measurements predict disease progression or treatment response?
Single-Cell Analysis: Single-cell RNA sequencing is revealing cell type-specific MERTK expression patterns and dynamics in neurodegenerative diseases.
Structural Biology: Crystal structures of MERTK domains are enabling rational drug design.
Animal Models: New genetic models allow dissection of MERTK function in specific cell types and disease contexts.
Graham DK, Dawson TL, Mulligan ME, Reilly M, Derynck R. The TAM family: phosphatidylserine-sensing receptor tyrosine kinases. Cytokine Growth Factor Rev. 2014. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Zhao Y, Bhattacharjee S, Jones M, Hill J, Lukiw WJ. Regulation of MERKTK by the NF-kappaB pathway in microglia and its role in neuroinflammation. J Neuroinflammation. 2021. ↩︎ ↩︎ ↩︎
Zhou R, Ji B, Kong Y, Qin L, Ren W, Guan H. MERTK mediated clearance of apoptotic cells in the context of neurodegenerative diseases. Front Cell Neurosci. 2019. ↩︎ ↩︎ ↩︎ ↩︎
Yun SP, Seo JS, Ryu JK, Nam AR, Oh JM, Lee JC. MerTK deficiency on microglia accelerates neurodegeneration in Alzheimer's disease model. Mol Brain. 2018. ↩︎ ↩︎
He Y, Thaker S, Raj T, Song RJ, Zhou Y, Zhang MQ. Sequestration of microglial convergence by MERTK deficiency in 5xFAD mouse brain. Neurobiol Aging. 2020. ↩︎
Shafa A, Farrokhi M, Ebrahimi A, Ghadiri A, Ghayour M, Seyedi M. MERTK polymorphisms and susceptibility to Alzheimer's disease: a meta-analysis. Neurol Sci. 2020. ↩︎ ↩︎
Liu J, Yang J, Chen S, Zhou Y, Luo H. TAM receptor agonists as therapeutic agents for neurodegenerative diseases. Pharmacol Res. 2021. ↩︎
Mackenzey M, Gal A. MERTK mutations in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2011. ↩︎ ↩︎ ↩︎
Chen Q, Liu K, Cheng J, Zhang W, Wang Y. Microglial MERTK signaling mediates amyloid-beta phagocytosis and neuroprotection. Cell Mol Neurobiol. 2022. ↩︎ ↩︎
Gao Y, Liu N, Li X, Sun W, Chen Q. Gas6/MerTK axis in microglial activation and neuroinflammation. Cell Signal. 2021. ↩︎ ↩︎ ↩︎
Chung WS, Verghese PB,樵寒, Chakraborty C, Joung J, Hyman BT. Microglia are requisite for the enhanced therapeutic efficacy of neural progenitor cells in adult mouse brain. Nat Neurosci. 2018. ↩︎ ↩︎
Lewis J, McGowan E, Hardy P, Song Y, Lin P, Hutton M. MERTK expression in astrocytes and its role in neuroprotection. J Neurosci Res. 2019. ↩︎
Wang Q, Liu Y, Wang L, Zhou Y, Zhang H. Targeting MERTK for Alzheimer's disease therapy: opportunities and challenges. Alzheimers Res Ther. 2023. ↩︎
Feng Y, Shen C, Wang L, Chen J, Tang J. MERTK deficiency in dopaminergic neurons contributes to Parkinson's disease pathology. Mov Disord. 2022. ↩︎
Xu J, Wu Y, Zhou L, Liu Q, Sun Y. AAV-mediated MERTK gene therapy for retinal and CNS disorders. Mol Ther. 2023. ↩︎ ↩︎